AI Stock Finder
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-06

GRAL vs VCYT: stock comparison and AI forecast

Grail, Inc. (GRAL) and Veracyte, Inc. (VCYT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Services-Medical Laboratories

GRAL Grail, Inc.

Price
$119.13 +89.3% · 6M
Market Cap
$5.32B
P/E Ratio
–
Size
mid-cap
AI Forecast
Full analysis →
Nasdaq · Services-Medical Laboratories

VCYT Veracyte, Inc.

Market Cap
$1.93B
P/E Ratio
25.0x
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

GRAL · VCYT

Key facts

  • GRAL is 2.8 times larger than VCYT by market capitalization ($5.32B against $1.93B).
  • GRAL carries 0.11 times debt per unit of equity, against 0.10 times for VCYT.
  • Both companies share the SEC industry classification Services-Medical Laboratories.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricGRALVCYT
Market Cap$5.32B$1.93B
P/E Ratio–25.00x
P/B Ratio2.17x1.35x
EPS$-9.44$0.96
Book Value/Share$54.93$17.83
Revenue/Share$3.73$7.24
FCF/Share$-6.99$2.01

Profitability & Margins

MetricGRALVCYT
ROE-16.6%–
ROA-14.9%–
ROIC-21.9%6.7%
Gross Margin–72.0%
Operating Margin-347.3%17.1%
Net Margin-243.8%–
EBT Margin-329.0%20.3%
Tax Rate25.9%-7.3%

Financial Health

MetricGRALVCYT
Current Ratio8.93x5.56x
Quick Ratio–5.25x
D/E Ratio0.11x0.10x
Financial Leverage1.11x1.10x
Working Capital$748M$384M

Cash Flow

MetricGRALVCYT
Operating Cash Flow-$306M$174M
Free Cash Flow-$312M$162M
Capital Spending-$6M-$12M
OCF Growth YoY–60.6%
FCF Growth YoY–64.9%
FCF/Sales-187.3%27.8%
CapEx/Sales3.5%2.0%

Operational Efficiency

MetricGRALVCYT
Asset Turnover0.06x0.37x
Receivables Turnover8.8x10.2x
Fixed Assets Turnover3.9x23.4x
Days Sales Outstanding42 days36 days

Income Statement

MetricGRALVCYT
Total Revenue$167M$582M
Operating Income-$579M$99M
Net Income-$406M–
R&D Expense$186M$110M
SG&A Expense$435M$325M

Dividend & Shareholder Information

MetricGRALVCYT
Shares Outstanding45M80M
EPS Growth–166.7%
FAQ

GRAL vs VCYT: stock comparison and AI forecast

Which is bigger, GRAL or VCYT?

GRAL is 2.8 times larger than VCYT by market capitalization ($5.32B against $1.93B).

Which one does Intratio's AI model rank higher, GRAL or VCYT?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.